Ekaterina Buvalaia’s Post

🎄On the 9th day of Christmas, EyePACS shared with me...  9 incredible benefits of offering retinal screenings in your practice. 1️⃣ Early detection of diabetic retinopathy 2️⃣ Improved patient outcomes 3️⃣ Increased compliance with care measures 4️⃣ Seamless integration with EyePACS tools 5️⃣ Empower providers with AI-driven insights 6️⃣ Enhance your clinic's reputation 7️⃣ Reduce referral burden for your patients 8️⃣ Meet population health goals 9️⃣ Affordable, scalable solutions Retinal screenings are a win for your patients and your practice. #12daysofchristmas

Introducing Delta III with OptiVision®! 🔍 Better Images Without Additional Radiation OptiVision® enhances visualization for ESWL, overcoming challenges like obesity and bowel gases with no extra radiation. Developed with top urologists, it ensures better diagnosis, treatment, and patient follow-up. Fully supported by HSL #MedicalInnovation #OptiVision #DeltaIII Dornier MedTech

Hot off the press! Just published in the September 2024 Journal of Wound Care, our first randomized controlled trial results show significant benefits of using ActiGraft PRO® to treat chronic neuropathic diabetic foot ulcers compared to the best practice standard of care. The ActiGraft Pro treatment resulted in a 51% healing rate compared to 18% in the control group and showed a shorter time to heal with a greater durability of wound closure. The study, “A Multicenter, Prospective, Randomized, Controlled Trial Comparing the Safety and Efficiency of Autologous Whole Blood Clot to Standard of Care in Patients with Chronic Diabetic Foot Ulcers,” included 119 patients at 13 sites in the US, 3 sites in South Africa and 1 in Turkey. These results underscore ActiGraft's effectiveness in enhancing patient outcomes and delivering a promising advancement in wound management. Learn more: Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomized controlled trial | Journal of Wound Care https://lnkd.in/gjyEGPQs #ActiGraft #RedDress #HealingisinOurBlood #Chronicwounds #Woundmanagement #DiabeticFootUlcers #Innovation

Our RCT study is now published! Jump-start wound healing with ActiGraft, an autologous whole blood wound care system applied weekly to drive significant healing progression. Once applied, it reignites the healing cascade, acting as a protective covering that supports the body's natural healing processes—accelerating your patients’ recovery journey. Let’s connect to discuss the evidence!

Wonderful article by Kaweh Mansouri about the Implandata Ophthalmic Products #EYEMATE system and how it is transforming glaucoma care in Glaucoma Today. In his article, Dr. Kaweh Mansouri - Discusses the game-changing EYEMATE system, an implantable device poised to redefine glaucoma care through continuous intraocular pressure monitoring. - He underscores how this innovative technology transcends the limitations of traditional methods like the Goldmann applanation tonometer by delivering real-time, long-term IOP data, enabling more precise and personalized disease management. - Drawing a compelling parallel, Dr. Mansouri likens the Eyemate system's transformative potential to the revolution sparked by continuous glucose monitoring in diabetes care. Find full article here: https://lnkd.in/eth44mdx

A lot of people ask me, why join RedDress Ltd. Today I share the why. Because I believe in #Innovation and #Hope. “Autologous therapies are considered the latest cutting-edge technology to be utilized in wound care." Dr. Robert Snyder DPM, Professor & Director of Clinical Research, Barry University, Florida. Chronic wound physiology has proven to be highly complex and intricate at the cellular level, involving multiple regulatory axes and signaling cascades. While commercial products have predominantly focused on “macro” factors (e.g., moisture and pressure), there remains ample opportunity to tailor wound care based on “micro” factors (e.g., cells, proteins, and peptides) for the treatments to provide extracellular matrix (ECM)–inspired biophysical cues and modulation of the immune response for adequate resolution of inflammation.* #ActiGraftPRO is one such innovative autologous therapy(and the only one using patient's whole blood) addressing the underlying challenges in wound microenvironment. Backed by a new RCT just published in the Journal of Wound Care, #ActiGraftPRO has demonstrated statistically significant healing outcomes offering a promising improvement over traditional care. This is over and above successfully treating close to 7000 patients (in the US and 30+ countries) since its FDA approval and a CE mark. *Ref: Benjamin R. Freedman et al., Breakthrough treatments for accelerated wound healing.Sci. Adv.9,eade7007(2023). #Fulfillingjob #MakingaDifference #patientQoL

According to many authors, the incidence of osteomyelitis in the world is increasing, doubling its rate between the 1960s and the 2010s. Despite the growing number of publications in this area, this disease still represents a major challenge for orthopedists around the world. This study aimed to highlight the continued importance and utility of plain radiography as a rapid, cost-effective, and readily accessible examination in the diagnostic process. Our study shows that radiographic findings in chronic osteomyelitis were universally observed in all patients studied, demonstrating a high degree of concordance among specialists. #osteomyelitis, #boneinfection, #musculoskeletaldisorders https://lnkd.in/ez7ypaqK

Minimally invasive techniques have continued to improve in recent years and Endovascular Therapy (ET) is now considered to be the primary treatment strategy for patients with Peripheral Arterial Disease (PAD). Nonetheless, specific lesion characteristics might influence the procedural success and the durability of endovascular reconstructions. Learn more about Risk Factor Analysis for Crossing Failure in Primary Antegrade Wire-Catheter Approach in this clinical investigation by the Journal of Endovascular Therapy: https://lnkd.in/enPKigdJ   #EndovascularTherapy #PeripheralArterialDisease #PAD #JournalCoverage #ScientificInvestigation #Terumo #TerumoSkillLab #TerumoIndiaSkillLab #TerumoKnowledgeLibrary #TerumoTraining #LearnWithTerumo #TerumoExperts #TerumoEducation #MedicalLearning #HealthTech #DiscoverHealthcare #MedicalCommunity #StayCurious #ElearningHealthcare

Today, we observe Leiomyosarcoma Awareness Day, a poignant reminder of the challenges faced by those battling this uncommon type of cancer affecting smooth muscle tissue. Leiomyosarcoma is aggressive, and the cause is not fully understood, which underscores the need for increased understanding among medical professionals and the broader community. Let's come together on this day to offer support, share knowledge, and advocate for greater funding for research and advanced medical treatments. By raising awareness and fostering collaboration, we can strive for improved outcomes and a better quality of life for individuals with leiomyosarcoma. Stay healthy and vigilant. If you experience any concerning symptoms such as persistent pain, unintentional weight loss, nausea, vomiting, or a lump under your skin, don't hesitate to reach out to your local physician for guidance and evaluation. Your health matters, so prioritize self-awareness and proactive medical care. To learn more about leiomyosarcoma, click here: https://lnkd.in/gHT4xCj5 #LeiomyosarcomaAwareness #EndLMS #HealthcareAwareness #StayHealthy